Reducing antipsychotic-induced weight gain in schizophrenia: A double-blind placebo-controlled study of reboxetine-betahistine combination

Psychopharmacology

Volumn 226, Issue 3, 2013, Pages 615-622

  Poyurovsky, Michael ^a,b   Fuchs, Camil ^c   Pashinian, Artashez ^a,b   Levi, Adva ^a   Weizman, Ronit ^c,e   Weizman, Abraham ^c,d  

^a Technion Medical School   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

^d GEHA MENTAL HEALTH CENTER   (Israel)

^e TEL AVIV COMMUNITY MENTAL HEALTH CENTER   (Israel)

Author keywords

Antipsychotics; Betahistine; Body mass index; Olanzapine; Reboxetine; Weight gain

Indexed keywords

BETAHISTINE; OLANZAPINE; PLACEBO; REBOXETINE;

ADULT; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; MENTAL HEALTH; PRIORITY JOURNAL; PULSE RATE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHIZOPHRENIA; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; WEIGHT GAIN;

ADRENERGIC UPTAKE INHIBITORS; ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BETAHISTINE; DOUBLE-BLIND METHOD; FEMALE; HISTAMINE AGONISTS; HUMANS; MALE; MIDDLE AGED; MORPHOLINES; SCHIZOPHRENIA; TREATMENT OUTCOME; WEIGHT GAIN; YOUNG ADULT;

EID: 84876480417     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-012-2935-2     Document Type: Article

References (33)

1. Ali AH, Yanoff LB, Stern EA, Akomeah A, Courville A, Kozlosky M, Brady SM, Calis KA, Reynolds JC, Crocker MK, Barak N, Yanovski JA (2010) Acute effects of betahistine hydrochloride on food intake and appetite in obese women: a randomized, placebo-controlled trial. Am J Clin Nutr 92(6):1290-1297
2. Andreasen NC (1983) Scale for the assessment of negative symptoms (SANS). University of Iowa, Iowa City
3. Andreasen NC (1984) Scale for the assessment of positive symptoms (SAPS). University of Iowa, Iowa City
4. Ball MP, Warren KR, Feldman S, McMahon RP, Kelly DL, Buchanan RW (2011) Placebo-controlled trial of atomoxetine for weight reduction in people with schizophrenia treated with clozapine or olanzapine. Clin Schizophr Relat Psychoses 5(1):17-25
5. Baptista T, ElFakih Y, Uzcátegui E, Sandia I, Tálamo E, Araujo de Baptista E, Beaulieu S (2008) Pharmacological management of atypical antipsychotic-induced weight gain. CNS Drugs 22(6):477-495
6. Barnes TRE (1989) A rating scale for drug-induced akathisia. Br J Psychiatry 154:672-676
7. Bymaster FP, Nelson DL, DeLapp NW, Falcone JF, Eckols K, Truex LL, Foreman MM, Lucaites VL, Calligaro DO (1999) Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr Res 37(1):107-122
8. Caemmerer J, Correll CU, Maayan L (2012) Acute and maintenance effects of non-pharmacologic interventions for antipsychotic associated weight gain and metabolic abnormalities: a meta-analytic comparison of randomized controlled trials. Schizophr Res 40(1-3):159-168
9. Deng C, Lian J, Pai N, Huang XF (2012) Reducing olanzapine-induced weight gain side effect by using betahistine: a study in the rat model. J Psychopharmacol 26(9):1271-1279
10. Fiedorowicz JG, Miller DD, Bishop JR, Calarge CA, Ellingrod VL, Haynes WG (2012) Systematic review and meta-analysis of pharmacological interventions for weight gain from antipsychotics and mood stabilizers. Curr Psychiatry 8(1):25-36
11. Fleckenstein AE, Lookingland KJ, Moore KE (1994) Differential role of histamine in mediating stress-induced changes in central dopaminergic neuronal activity in the rat. Brain Res 653(1-2):267-272
12. Fossati A, Barone D, Benvenuti C (2001) Binding affinity profile of betahistine and its metabolites for central histamine receptors of rodents. Pharmacol Res 43(4):389-392
13. Fukagawa K, Sakata T, Shiraishi T, Yoshimatsu H, Fujimoto K, Ookuma K, Wada H (1989) Neuronal histamine modulates feeding behavior through H1-receptor in rat hypothalamus. Am J Physiol 256(3 Pt 2):R605-R611
14. Gohlke JM, Dhurandhar EJ, Correll CU, Morrato EH, Newcomer JW, Remington G, Nasrallah HA, Crystal S, Nicol G, Adipogenic and Metabolic Effects of APDs Conference Speakers, Allison DB (2012) Recent advances in understanding and mitigating adipogenic and metabolic effects of antipsychotic drugs. Front Psychiatry 3:62
15. Guy W (1976) ECDE assessment manual for psychopharmacology. Revised DHEW Pub (ADM). National Institute of Mental Health, Rockville
16. Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62
17. Kanders BS, Forse RA, Blackburn GL (1991) Methods in obesity. In: Rakel RE (ed) Conn's current therapy. Saunders, Philadelphia, pp 524-532
18. Kim SF, Huang AS, Snowman AM, Teuscher C, Snyder SH (2007) From the cover: antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. Proc Natl Acad Sci U S A 104(9):3456-3459
19. Korotkova TM, Sergeeva OA, Ponomarenko AA, Haas HL (2005) Histamine excites noradrenergic neurons in locus coeruleus in rats. Neuropharmacology 49(1):129-134
20. Kroeze WK, Hufeisen SJ, Popadak BA, Renock SM, Steinberg S, Ernsberger P, Jayathilake K, Meltzer HY, Roth BL (2003) H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 28(3):519-526
21. Lacour M, Sterkers O (2001) Histamine and betahistine in the treatment of vertigo: elucidation of mechanisms of action. CNS Drugs 15(11):853-870
22. Masaki T, Yoshimatsu H, Chiba S, Watanabe T, Sakata T (2001) Central infusion of histamine reduces fat accumulation and upregulates UCP family in leptin-resistant obese mice. Diabetes 50(2):376-384
23. Mayer AF, Schroeder C, Heusser K, Tank J, Diedrich A, Schmieder RE, Luft FC, Jordan J (2006) Influences of norepinephrine transporter function on the distribution of sympathetic activity in humans. Hypertension 48(1):120-126
24. Poyurovsky M, Pashinian A, Levi A, Weizman R, Weizman A (2005) The effect of betahistine, a histamine H1 receptor agonist/H3 antagonist, on olanzapine-induced weight gain in first-episode schizophrenia patients. Int Clin Psychopharmacol 20(2):101-103
25. Poyurovsky M, Fuchs C, Pashinian A, Levi A, Faragian S, Maayan R, Gil-Ad I (2007) Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study. Psychopharmacology (Berl). 192(3):441-448
26. Reynolds GP, Kirk SL (2010) Metabolic side effects of antipsychotic drug treatment - pharmacological mechanisms. Pharmacol Ther 125(1):169-179
27. Rossi R, Del Prete E, Scharrer E (1999) Effect of the H1-histamine receptor agonist betahistine on drinking and eating behavior in pygmy goats. Physiol Behav 66(3):517-521
28. Schatzberg AF (2000) Clinical efficacy of reboxetine in major depression. J Clin Psychiatry 61(Suppl 10):31-38
29. Shigemoto Y, Fujii Y, Shinomiya K, Kamei C (2004) Participation of histaminergic H1 and noradrenergic alpha 1 receptors in orexin A-induced wakefulness in rats. Brain Res 1023(1):121-125
30. Simpson GM, Angus JWS (1970) A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 212:11-19
31. Spina E, Scordo MG, D'Arrigo C (2003) Metabolic drug interactions with new psychotropic agents. Fundam Clin Pharmacol 17:517-538
32. Szelag A, Trocha M, Merwid-Lad A (2001) Betahistine inhibits food intake in rats. Pol J Pharmacol 53(6):701-707
33. Wirshing DA, Wirshing WC, Kysar L, Berisford MA, Goldstein D, Pashdag J, Mintz J, Marder SR (1999) Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry 60(6):358-363